HighTower Advisors’s 10x Genomics TXG Stock Holding History

HighTower Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-102,500	Closed	-$103K	–	4064
2025 Q2	$103K	Buy	+102,500	New	+$934K	﹤0.01%	3463

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's TXG Position: Q4 2025 in Review

HighTower Advisors sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 32,920 shares — an estimated $385K sold.

HighTower Advisors first reported a position in TXG in Q2 2020 and held it in 11 quarters. The position peaked at $1.73M in Q1 2021. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

HighTower Advisors reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 32,920 10x Genomics shares in Q4 2025, an estimated $385K.
HighTower Advisors first reported a position in 10x Genomics in Q2 2020 and held it in 11 quarters.
HighTower Advisors's 10x Genomics position peaked at $1.73M in Q1 2021.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.